
Magna operating profit jumps 58% despite GAAP loss on asset sales
Magna International (NYSE:MGA) delivered a strong operational performance for the first quarter of 2026, characterized by significant margin expansion and robust cash returns to shareholders.
The Canadian-based auto parts titan reported total sales of $10.4 billion, a 3% increase over the same period last year.
The growth was driven by higher global vehicle production and the launch of new programs, particularly in its Power & Vision and Seating segments.
The company’s underlying profitability showed marked improvement as supply chain pressures continued to ease.
Adjusted EBIT jumped 58% to $558 million, while adjusted diluted earnings per share (EPS) surged 77% to $1.38, comfortably exceeding analyst expectations.
Management attributed the gains to better capacity utilization and the success of ongoing cost-reduction initiatives across its global manufacturing footprint.
However, on a GAAP basis, Magna reported a net loss of $12 million.
The deficit was primarily due to a $485 million pre-tax non-cash loss on assets held for sale, a move linked to the company’s strategic portfolio optimization and the divestiture of non-core business units.
Despite this accounting charge, Magna’s liquidity remained strong, allowing the company to return $575 million to shareholders during the quarter through a combination of dividends and share repurchases.
Looking ahead, Magna reaffirmed its full-year 2026 financial outlook, signaling confidence in the stability of the global automotive market.
The company continues to project total sales between $41.5 billion and $43.1 billion, with adjusted EPS expected to range from $6.25 to $7.25.
Free cash flow for the year is forecast to remain robust at $1.6 billion to $1.8 billion, providing ample capital for continued investment in electric vehicle architectures and automated driving technologies.
More from United States
Oil prices extend gains as Middle East tensions rise
Magna posts higher Q3 earnings despite 4% sales decline
BP Q3 profit jumps to $8.46 billion as debt falls
Sanofi Q3 sales rise 16.2% to €14.44 billion
AstraZeneca revenue advances 7% in Q3 to $16.21 billion
First Northern profit climbs 11.1% to $16.8 million